Home › Kanser sa Bato (Renal Cell Carcinoma) › Oregon › Portland
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Portland, OR
Isang pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Portland. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi ang layo
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #51, Portland
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Nagre-recruitPhase 1/2
- Northwest Cancer Specialists, P.C., Portland
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Nagre-recruitPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- at 1 pa
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Providence Cancer Institute, Portland
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Nagre-recruitPhase 1/2
- Oregon Health & Science University (3485 S. Bond), Portland
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Nagre-recruitPhase 4
- OHSU Knight Cancer Institute, Portland
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Nagre-recruitPhase 1
- Oregon Health & Science University, Portland
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Nagre-recruitPhase 3
- Kaiser Permanente Northwest, Portland
- Oregon Health and Science University, Portland
Pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) sa ibang lungsod
- Houston, TX35 pag-aaral
- New York City, NY27 pag-aaral
- Nashville, TN23 pag-aaral
- Dallas, TX23 pag-aaral
- St. Louis, MO23 pag-aaral
- Los Angeles, CA20 pag-aaral
- Boston, MA16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Queens, NY15 pag-aaral
- Cleveland, OH14 pag-aaral
Iba pang pag-aaral sa Portland
- Non-Small Cell Lung Cancer46 pag-aaral
- Kanser (lahat ng uri)34 pag-aaral
- Kanser sa Suso33 pag-aaral
- Kanser sa Prostate33 pag-aaral
- Metastatic Cancer29 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Kanser sa Baga26 pag-aaral
- Acute Myeloid Leukemia25 pag-aaral
- Kanser ng Endometrium24 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg19 pag-aaral
- Kanser sa Pancreas19 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.